Navigation Links
Green Tea May Help Prevent Oral Cancer
Date:11/5/2009

Small study reports evidence of cancer-fighting properties

THURSDAY, Nov. 5 (HealthDay News) -- A new study appears to add to growing evidence that green tea might help protect against cancer.

U.S. researchers gave 41 volunteers with pre-malignant mouth lesions green tea extract for three months at doses of 500 milligrams per meter squared (mg/m2), 750 mg/m2 or 1,000 mg/m2. The extract was taken by mouth. Other participants took a placebo.

The study found that about 59 percent of people taking the highest dose of the green tea extract showed a clinical response, compared with 18 percent of those who took a placebo. The researchers also noted a trend toward improvement in certain biomarkers that could predict cancer development.

During the study period of about 28 months, 15 people developed oral cancer. People who took the green tea extract and those who didn't were equally likely to develop the cancer. However, people who had mild to moderate dysplasia, or abnormal cell growth, at the start of the study took longer to develop oral cancer if they took the green tea extract.

Study author Dr. Vassiliki Papadimitrakopoulo, a professor in the department of thoracic/head and neck medical oncology at the University of Texas M.D. Anderson Cancer Center, said the findings were encouraging but did not provide definitive proof that green tea can prevent cancer.

"This is a phase 2 study with a very limited number of patients who took what would be the equivalent of drinking eight to 10 cups of green tea every single day. We cannot with certainty claim prevention benefits from a trial of this size," Papadimitrakopoulo said in a news release from the American Association for Cancer Research.

"The goal of this kind of research is to determine whether or not these supplements have long-term prevention effects," Papadimitrakopoulo noted. "More research, including studies in which individuals at high
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
2. The Breema Center Offers Bodywork Mini-Sessions and Demonstrations at the San Francisco Green Festival
3. New Hospitals Therapeutic Design Supports Healing, Green Practices
4. Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices
5. Green Spaces Boost the Body and the Mind
6. Cystic Fibrosis Foundation Names Greenberg Traurig Attorney D. Porpoise Evans Among the 40 Under 40 Outstanding Lawyers of Miami-Dade County
7. Statement of Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on The Senate Finance Committees Health Reform Plan
8. Greenway Medical Technologies EHR Platform Continues to Lead Interoperability Efforts With Participation in Key Health IT Integration Showcases
9. South Florida Law Firm Steinger, Iscoe & Greene Offers Around-the-Clock Free Legal Advice to Broward General Contaminated IV Patients
10. Medical Travel Company Satori World Medical Announces Relationship with Managing General Underwriter GreenWood International Insurance Services (GWI)
11. Botsford Hospital Cancer Center Earns Silver LEED Certification from the U.S. Green Building Council
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 1Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 1CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 3Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 1Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 2